MD Anderson Cancer Center University of Texas
Welcome,         Profile    Billing    Logout  
 79 Trials 
132 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Recruiting
4
140
Europe
Opicapone 50 mg, BIA 9-1067, Matching placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
12/22
12/22
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/25
07/25
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Recruiting
4
268
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
12/24
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct

Recruiting
4
150
RoW
Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences
Diarrhoea;Acute, Diarrhea Travelers
09/24
12/24
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Recruiting
4
60
US
Tamsulosin Hydrochloride
Feiran Lou, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
06/25
12/25
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Recruiting
3
300
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
11/23
12/24
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Calendar Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting
3
50
US
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Planned Parenthood League of Massachusetts
Abortion
07/24
09/24
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, DAIICHI SANKYO. INC., Daiichi Sankyo, Inc.
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
08/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
MorphoSys AG
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Active, not recruiting
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Calendar Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, Inc., AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active, not recruiting
3
93
Europe, RoW
Efanesoctocog alfa, BIVV001
Swedish Orphan Biovitrum, Syneos Health
Hemophilia A, Severe
05/26
05/26
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L metastatic NSCLC (based on TROPION Lung08 trial)
Calendar Jan 2024 - Dec 2024: Data from TROPION-Lung08 trial for advanced or metastatic NSCLC
Recruiting
3
740
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
02/28
04/28
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
975
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, Keytruda, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Recruiting
2/3
166
US
TheraBionic Device, Placebo Device, Quality of Life Assessment
THERABIONIC INC., National Cancer Institute (NCI)
Hepatocellular Carcinoma
10/24
10/24
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Recruiting
2/3
336
Europe
Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar
Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center
Injury of Ureter During Surgery (Disorder)
10/25
11/25
ESTRELLA, NCT04764448 / 2020-003313-35: A Study of Belcesiran in Patients With AATLD

Active, not recruiting
2
46
Europe, Canada, US, RoW
Belcesiran, Placebo
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Alpha 1-Antitrypsin Deficiency
12/23
12/26
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
115
US
RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, Ranibizumab, RGX-314 Dose 3, Local steroid, Topical steroid
AbbVie, AbbVie
Neovascular Age-Related Macular Degeneration (nAMD)
10/23
01/24
NCT04832724: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Completed
2
60
US
RGX-314
AbbVie
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
10/23
03/24
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)

Recruiting
2
40
Europe
MC2-25 cream, MC2-25 vehicle
MC2 Therapeutics
Vulvar Lichen Sclerosus
11/24
11/24
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Active, not recruiting
2
13
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Thermal Burn
12/24
12/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, Placebo
Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
EAD501, NCT05607615: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

Recruiting
2
90
US
Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline
Cyclo Therapeutics, Inc.
Alzheimer's Disease
03/24
03/24
NCT05569252 / 2022-000676-19: A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Completed
2
64
Europe, US
DS-1211b, Placebo
Daiichi Sankyo, PXE International
Pseudoxanthoma Elasticum
11/23
11/23
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial

Not yet recruiting
2
50
Europe
EBX-102, IMT capsules, Placebo
Imperial College London
Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
02/26
05/27
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
100
RoW
Tis-U-Sol
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital
Nasopharyngeal Neoplasms
05/24
05/26
NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
01/25
04/25
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Recruiting
2
20
US
Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device
Stephan Grupp MD PhD
Systemic Lupus Erythematosus, Systemic Sclerosis
12/26
05/31
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Not yet recruiting
2
25
RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Freezing of Gait Symptoms in Parkinson's Disease
12/24
03/25
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Recruiting
2
240
US
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
GeoVax, Inc., National Cancer Institute (NCI)
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
03/25
03/26
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting
2
146
Japan, US, RoW
TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel
Toray Industries, Inc
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
NCT05205330: A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Active, not recruiting
1/2
28
Europe
CR6086, AGEN2034, Balstilimab
Rottapharm Biotech, Agenus Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
10/23
12/24
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Recruiting
1/2
24
US
DS-7011a, Placebo
Daiichi Sankyo
Systemic Lupus Erythematosus
03/25
03/25
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
300
Europe, US
ASTX029
Astex Pharmaceuticals, Inc.
Solid Tumor, Adult
06/24
12/25
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Recruiting
1/2
12
Europe
DS-2325a, Placebo
Daiichi Sankyo
Netherton Syndrome
11/24
11/24
SQ3370-001, NCT04106492: Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

Recruiting
1/2
145
US, RoW
SQ3370
Shasqi, Inc.
Cancer
08/24
07/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/24
03/27
EPCORE NHL-1, NCT03625037 / 2017-001748-36: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Checkmark Subgroup data analysis from EPCORE NHL-1 for r/r/ B-cell lymphoma at ASH 2022
Dec 2022 - Dec 2022: Subgroup data analysis from EPCORE NHL-1 for r/r/ B-cell lymphoma at ASH 2022
Checkmark Updated data from trial for r/r DLBCL and follicular lymphoma
Apr 2021 - Sep 2021: Updated data from trial for r/r DLBCL and follicular lymphoma
Checkmark Safety and complete response data from trial for B-cell lymphoma at ASH 2020
More
Active, not recruiting
1/2
666
Europe, Canada, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Genmab, AbbVie
DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL)
03/25
01/29
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention

Recruiting
1/2
240
US
Group Exercise, Behavioral Training
Iowa State University
Exercise, Frailty, Arthritis, Accidental Falls
05/25
05/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
430
Japan, US
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Recruiting
1/2
65
Europe, Canada, US, RoW
Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group
Acute Myeloid Leukemia
05/27
05/27
U31402-A-U102, NCT03260491: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Completed
1
80
US
DS-7011a, Placebo
Daiichi Sankyo, Inc.
Systemic Lupus Erythematosus
01/23
03/23
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Completed
1
64
US
DS-2325a, Placebo
Daiichi Sankyo, Inc.
Netherton Syndrome
01/23
01/23
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Active, not recruiting
1
56
US
SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control
South Rampart Pharma, LLC
Pain
10/23
02/24
NCT05844202: Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention

Completed
1
130
RoW
Alveavax-v1.2, Alveavax, Janssen Ad26.COV2.S, Janssen
Alvea Holdings, LLC
Sars-CoV-2 Infection
03/23
03/23
NCT05583669: A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Completed
1
24
US
DS-2325a, Placebo
Daiichi Sankyo, Inc.
Netherton Syndrome
05/23
05/23
NCT05633745: A Study to Assess NEU-723 in Healthy Participants

Terminated
1
40
RoW
NEU-723, Placebo
Neuron23 Inc.
Healthy
06/23
06/23
ICVP, NCT04634383: A Phase I Feasibility Study of an Intracortical Visual Prosthesis () for People With Blindness

Recruiting
1
5
US
WFMA - wireless floating microelectrode array, ICVP System, ICVP, Intracortical Visual Prosthesis
Illinois Institute of Technology, National Institute of Neurological Disorders and Stroke (NINDS), Rush University Medical Center, The Chicago Lighthouse, The University of Texas at Dallas, University of Chicago, Johns Hopkins University
Ocular Injury, Optic Nerve Diseases, Photoreceptor Degeneration, Blindness,Acquired
08/23
08/23
NCT05394675: A Study of DS-9606a in Patients With Advanced Solid Tumors

Recruiting
1
125
Europe, US
DS-9606a
Daiichi Sankyo
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor
02/26
02/26
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Completed
1
10
RoW
89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx
Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd.
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
11/23
11/23
KEYNOTE-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Recruiting
1
115
Europe, US
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Daiichi Sankyo, AstraZeneca UK Limited, Merck Sharp & Dohme LLC
Breast Cancer, Non-small Cell Lung Carcinoma
12/24
08/25
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Active, not recruiting
1
42
US
EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
Emmecell
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
10/24
10/24
KEYNOTE-B43, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Calendar Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, Pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
06/25
06/25
NCT06244485: A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Recruiting
1
210
Japan, US
Valemetostat tosylate, DS-3201b, T-DXd, DS-8201a, ENHERTU, Dato-DXd, DS-1062a
Daiichi Sankyo
Advanced Solid Tumor
11/28
11/28
NCT05755191: A Study to Assess NEU-411 in Healthy Participants

Completed
1
147
RoW
NEU-411, Placebo
Neuron23 Inc.
Healthy
06/24
06/24
NCT05628961: Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

Recruiting
1
42
US
HOPO 14-1
SRI International
Toxicity;Chemical
04/24
04/24
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Active, not recruiting
1
130
US
BBP-398 (Formerly known as IACS-15509)
Navire Pharma Inc., a BridgeBio company
Tumor, Solid
05/24
02/25
NCT05940571: First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

Recruiting
1
41
Europe
MBF-362
Medibiofarma S.L.
Cancer
10/24
11/24
THB335-101, NCT06425861: A First in Human Trial Evaluating THB335 in Healthy Participants

Recruiting
1
56
US
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Third Harmonic Bio, Inc.
Healthy
03/25
03/25
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Recruiting
1
140
Japan, US
DS-6000a, R-DXd
Daiichi Sankyo, Inc.
Renal Cell Carcinoma, Ovarian Tumor
10/24
10/24
NCT04953910: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Recruiting
1
27
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting
1
36
RoW
89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma
12/24
12/26
NCT04953897: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Recruiting
1
18
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT05029960: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Recruiting
1
30
US
Brivaracetam
University of Rochester
Brain Tumor
12/24
12/24
TROPION-PanTumor01, NCT03401385: First-in-human Study of DS-1062a for Advanced Solid Tumors

Checkmark Data from TNBC cohort of TROPION-PanTumor01 trial for TNBC at SABCS 2022
Dec 2022 - Dec 2022: Data from TNBC cohort of TROPION-PanTumor01 trial for TNBC at SABCS 2022
Checkmark Data from TROPION-PanTumor01 trial for unresectable or metastatic HR+/HER2− breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from TROPION-PanTumor01 trial for unresectable or metastatic HR+/HER2− breast cancer at SABCS 2022
Checkmark Presentation of results from TROPION-PanTumor01 trial for TNBC cohort at SABCS 2022
More
Recruiting
1
890
Japan, US
Datopotamab Deruxtecan (Dato-DXd), DS1062a, Study treatment, Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., AstraZeneca
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
01/25
01/25
NCT05859724: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Recruiting
1
140
Europe, Canada, US
NM26-2198, Placebo
Numab Therapeutics AG, Kaken Pharmaceutical Co., Ltd.
Atopic Dermatitis
02/25
04/25
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
IPAX-2, NCT05450744: 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma

Recruiting
1
12
Europe, RoW
131I-IPA, 18F-FET
Telix International Pty Ltd
Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
06/25
06/25
NCT05765851: A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Recruiting
1
78
Europe, Canada, US
DS-1103a, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Advanced Solid Tumor, Breast Cancer
06/26
06/26
NCT06279728: Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Available
N/A
Europe, US
Datopotamab deruxtecan, Dato-DXd, DS-1062a
Daiichi Sankyo, AstraZeneca
Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
 
 
NCT04886544: Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

Completed
N/A
72
Europe
YVOIRE Y-Solution 720
LG Chem
Jaw Volume Deficit
05/22
01/23
TMSVS, NCT04925232: Transcranial Magnetic Stimulation For Visual Snow Syndrome

Completed
N/A
10
US
Transcranial Magnetic Stimulation device, TMS
University of Colorado, Denver
Visual Snow Syndrome
11/22
11/22
NCT05133973: Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic Patients

Recruiting
N/A
12
Europe
FiberSense CGM
EyeSense GmbH
Diabetes
12/22
12/22
PAROS, NCT04745520: Randomized Clinical Trial of Rib Fixation Versus Medical Analgesia in Uncomplicated Rib Fractures on Pain Control.

Recruiting
N/A
102
Europe
Rib fixation, Analgesia
Benoît Bédat, Centre Hospitalier Universitaire Vaudois, Hôpital du Valais
Rib Fractures
03/23
03/24
MNH, NCT01073475: Maternal Newborn Health Registry

Recruiting
N/A
950000
US, RoW
There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
NICHD Global Network for Women's and Children's Health
Pregnancy Outcome Trends in Low-resource Geographic Areas
01/25
01/25
NCT04445207: Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

No Longer Available
N/A
US
Convalescent Plasma
Jonathan Gerber
COVID, Sars-CoV2, Corona Virus Infection
 
 
NCT03929731: Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)

Recruiting
N/A
72
RoW
Indocyanine Green Angiography, Optical Coherence Tomography-Angiography, Fundus photography, Fundus fluorescein, Optical Coherence Tomography
Singapore National Eye Centre
Polypoidal Choroidal Vasculopathy
06/25
06/25
NCT05769751: A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Completed
N/A
865
RoW
Electronic medical record and hospital information system or other available resources
Daiichi Sankyo, Inc.
HER2-positive Breast Cancer
07/23
07/23
BIOPATTERN, NCT06259019: Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease

Recruiting
N/A
300
Europe
Liquid Biopsy System (LBS), LBS
PlaqueTec Ltd, Royal Papworth Hospital
Coronary Artery Disease
05/25
07/25
NCT04622969: The Healthy Child Development Program Study

Completed
N/A
63
US
Healthy Child Development Program
University of South Carolina
Child Behavior, Child Health, Child, Preschool, Parents
01/24
01/24
B-Free, NCT03928236: Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium

Active, not recruiting
N/A
15886
Canada, US
Limited Intraoperative Benzodiazepine, Liberal Intraoperative Benzodiazepine
Population Health Research Institute
Delirium, Post-cardiac Surgery
07/24
07/24
CHIRP, NCT05218824: Collection of Head Images During Radiotherapy

Active, not recruiting
N/A
32
RoW
University of Sydney, Western Sydney Local Health District
Head and Neck Neoplasms, Radiation Therapy Complication
12/24
12/24
EUROPA T-DXd, NCT05458401: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Completed
N/A
256
Europe
Trastuzumab deruxtecan, T-DXd
Daiichi Sankyo
HER2-positive Breast Cancer
12/23
12/23
OPBIM, NCT06353464: A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation

Recruiting
N/A
80
US
Ensure and Water
Drexel University
Obesity
09/25
09/25
NCT06099639: Medical Access Program for Patritumab Deruxtecan

Available
N/A
US
HER3-DXd, U3-1402
Daiichi Sankyo
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
 
 
HHiNPWT7DC, NCT05559697: Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days

Completed
N/A
16
US
Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system
DeRoyal Industries, Inc., Lincoln Memorial University
Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation
03/24
03/24
MEE, NCT04730700: Evaluation of Multi-Tined Expandable Electrode () Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management.

Recruiting
N/A
50
US
Radiofrequency Ablation with MEE, Conventional Medical Management
University of Kansas Medical Center
Chronic Low-back Pain
11/23
11/23
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Active, not recruiting
N/A
3300
RoW
Mevalotin
Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd.
Dyslipidemia
04/25
04/25
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Completed
N/A
450
RoW
Daiichi Sankyo Co., Ltd.
Gastric Cancer
11/23
11/23
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

Terminated
N/A
7
US
One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
Wake Forest University Health Sciences
Childhood Cancer
05/20
05/20
NCT05851573: Stepped Care for Aphasia

Completed
N/A
11
US
Psychosocial intervention
Medical University of South Carolina
Aphasia, Stroke
12/23
12/23
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Recruiting
N/A
800
RoW
Trastuzumab deruxtecan, T-DXd
Daiichi Sankyo
HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
03/28
03/28
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA

Active, not recruiting
N/A
46
US
POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care)
University of Arkansas
Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis
04/23
12/24
 

Download Options